Login    Join free Add to favorites    中文
home > news > PerkinElmer Purchases GE Healthcare's Catalog Radiochemicals ...
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
PerkinElmer Purchases GE Healthcare's Catalog Radiochemicals ...

hits:2620     Date:09/22/09
PerkinElmer Purchases GE Healthcare's Catalog Radiochemicals, SPA Reagents and Cytostar-T Plate Assets

PerkinElmer adds offerings for detection and screening of potential new drugs, expands radiolabeling and bead-based assay technologies

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and their environment, today announced that it has purchased the assets of GE Healthcare's 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay (SPA) reagents and Cytostar-T plate product lines.

The Catalog Radiochemical products are used for a variety of research applications, including screening of potential drug candidates through binding assays. The SPA bead-based light-emitting assay and Cytostar-T plate technologies are offerings that enable the automation of High Throughput Screening (HTS) processes, to help drug discovery researchers quickly and accurately determine if potential new drug compounds are effective against their intended disease targets.

GE Healthcare will be working closely with PerkinElmer to ensure a smooth transition of its manufacturing and technical support activities and to minimize disruption for customers during the transition period.

Richard M. Eglen, PhD, president, Bio-discovery, PerkinElmer, said, "PerkinElmer is delighted to announce this enhancement to our reagents assets. We expect that the incorporation of these technologies will strengthen our industry-leading GPCR and Kinase research product lines, and complement our HTS and research reagent solutions. This asset purchase reinforces PerkinElmer's continued position as the leading company in HTS radiochemicals and related instruments, as we remain committed to supporting critical radiochemicals-based research."

As a result of this asset purchase, PerkinElmer will now provide the world's largest selection of high-quality radiolabeled compounds to the global scientific community. In addition, the company plans to continue to expand its NEN(R) radiochemical portfolio, as well as offer its extensive lines of readers, nuclear counters and other high-performance instrumentation that provide customers with complete application solutions in radiometric detection. For more information, please visit: www.perkinelmer.com/committedtorads.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2 billion in 2008, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

SOURCE FROM PerkinElmer, Inc.

Related News>> more
advertisement

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙